H.C. Wainwright cuts Tempus AI stock price target to $64 on wider losses

Tempus AI reported Q1 revenue of $348.1 million, up 36.1% year over year and slightly above estimates, but posted a wider net loss of $125.9 million, or $0.71 per diluted share. The company raised fiscal 2026 revenue guidance to $1.59 billion-$1.60 billion and expects about $65 million in adjusted EBITDA, while H.C. Wainwright cut its price target to $64 from $95 on a lower 7.0x EV/revenue multiple. TD Cowen separately raised its target to $68 from $65, leaving the shares supported by strong growth but weighed by losses and valuation concerns.

Analysis

TEM is transitioning from a pure growth narrative to a capital-intensity and financing story. The guidance raise helps near-term sentiment, but the bigger tell is that the market is now demanding proof that incremental revenue can outgrow incremental cash burn; otherwise, every percentage point of growth is being discounted by balance-sheet dilution risk. The convert issuance gives management runway, but it also caps upside in the short run because equity investors will increasingly focus on dilution-adjusted per-share value rather than top-line momentum.

The second-order read-through is that the Merck/Gilead collaborations are more valuable as validation than as near-term earnings contributors. In this kind of platform business, strategic logos can improve negotiating leverage with other pharma partners and accelerate enterprise adoption, but they also raise expectations for monetization timing that management may not be able to meet over the next 2-4 quarters. If execution slips, the stock can re-rate sharply because the market is already rewarding the story on future optionality.

For MDT, the ALERT data is not just a product win; it strengthens the case for software-enabled clinical workflow as a margin-accretive growth layer inside an otherwise mature medtech profile. The market tends to underappreciate how evidence-generating data can convert into hospital decision support and procedural pull-through over 12-24 months, especially if it creates reimbursement or guideline tailwinds. The risk is that adoption velocity disappoints if the integration burden at health systems is higher than implied by the trial result.

Key Decisions for Investors

• Trim/underweight TEM on strength over the next 1-2 weeks: the convert plus wider loss profile creates a poor risk/reward setup until the market sees 1-2 more quarters of EBITDA progression.
• If long TEM, express it via a call spread or limited-risk structure for 3-6 months rather than common; upside is tied to multiple expansion, while downside is amplified by dilution and earnings revisions.
• Consider a pair trade: long MDT / short TEM for 1-2 quarters. MDT offers steadier monetization of digital workflow upside, while TEM is more exposed to execution and financing overhang.
• Use any TEM pullback into the low-$40s to reassess for a tactical long only if revenue growth remains >25% and adjusted EBITDA inflects meaningfully; otherwise the stock remains a story-stock, not a fundamentals compounder.
• For conservative portfolios, wait for clearer evidence that partner wins convert into durable gross-margin expansion before adding TEM; the current setup favors trading around volatility, not long-term conviction.